Regeneron Pharmaceuticals, Inc. (REGN) Price and Market Data

Regeneron Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing treatments for eye disease, cardiovascular conditions, cancer, and inflammatory disorders. Its marketed products include low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other retinal diseases; Dupixent in immunology; Praluent for lowering LDL cholesterol; Libtayo in oncology; and Kevzara for rheumatoid arthritis. Regeneron is also advancing monoclonal and bispecific antibody programs with Sanofi, other partners, and through internal research, while early-stage collaborations add new technologies to its pipeline, including RNAi with Alnylam and CRISPR-based gene editing with Intellia.